Quality of Life Research

, Volume 22, Issue 10, pp 2777–2786 | Cite as

Pain questionnaire performance in advanced prostate cancer: comparative results from two international clinical trials

  • Donald W. RobinsonJr.
  • Ning Zhao
  • Fitzroy Dawkins
  • Ming Qi
  • Dennis Revicki
Article
First Online:
Accepted:

Abstract

Purpose

To compare pain assessment questionnaires commonly used in advanced prostate cancer trials and to determine the psychometric characteristics and longitudinal relationships by contrasting questionnaire data from two international phase 2 trials.

Methods

Scores from the Present Pain Intensity (PPI) question of the McGill Pain Questionnaire, the pain intensity scale of the Brief Pain Inventory (BPI), and the Functional Assessment of Cancer Therapy-Prostate (FACT-P) were analyzed using Pearson correlation, intraclass correlation coefficient, and Cronbach’s α, respectively. Concordance was evaluated with Cohen’s kappa coefficient and McNemar test at baseline (n = 224) and two subsequent observations.

Results

PPI and FACT-P scores were associated with the BPI score at baseline for Trials 1 and 2: PPI r = 0.66 and 0.80, respectively (P < 0.001); FACT-P (pain scale) r = −0.76 and −0.82, respectively (P < 0.001). However, concordance analysis revealed that the BPI identified pain (score > 0) at higher rates than the PPI: at baseline, BPI: 89 % (64/72) and 77 % (95/124), PPI: 68 % (49/72) and 64 % (79/124) [Trials 1 and 2, respectively; McNemar test (P < 0.001) for both studies]. The FACT-P pain scale identified pain similarly to the BPI pain intensity scale; longitudinal analysis produced comparable findings. All pain scales met standard psychometric acceptability criteria, but the BPI and FACT-P performed better than the PPI.

Conclusions

Data suggest the BPI pain intensity and FACT-P pain scales are better than the PPI question at capturing the pain experience among patients with advanced prostate cancer. Additional comparative research is needed in larger population samples.

Keywords

Prostate cancer Pain Symptoms Psychometrics Epidemiology Quality of life 

Abbreviations

ALP

Alkaline phosphatase

BMI

Body mass index

BPI

Brief Pain Inventory

CRP

C-reactive protein

CRPC

Castrate-resistant prostate cancer

ECOG

Eastern Cooperative Oncology Group

ECOG PS

Eastern Cooperative Oncology Group performance status

ESA

Erythropoietin-stimulating agents

FACT

Functional Assessment of Cancer Therapy

FACT-P

Functional Assessment of Cancer Therapy-Prostate

FACT-PCS

Functional Assessment of Cancer Therapy-Prostate prostate cancer scale

Hgb

Hemoglobin

HRQoL

Health-related quality of life

ICC

Intraclass correlation coefficient

LDH

Lactate dehydrogenase

NA

Data not available

PPI

Present Pain Intensity

PSA

Prostate-specific antigen

SD

Standard deviation

T1

Trial 1

T2

Trial 2

This is a preview of subscription content, log in to check access.

Notes

Acknowledgments

The authors thank Lyn Lai, Mary Sorrentino, and Rob Achenbach of the Medical Affairs Publications Group of Janssen Services, LLC, for their editorial and submission support. Brenda Foster, MD, PhD, provided clinical insight into an early draft of this manuscript. We greatly appreciate the patients who participated in this study and shared their perceptions of health with us.

Conflict of interest

Janssen Biotech, Inc., sponsored the study. Fitzroy Dawkins, Ming Qi, Donald Robinson Jr., and Ning Zhao are Janssen Research & Development, LLC, employees. Dennis Revicki was a Janssen Global Services, LLC, consultant, but received no compensation for this work.

References

  1. 1.
    Lee, D. J., Cha, E. K., Dubin, J. M., Beltran, H., Chromecki, T. F., Fajkovic, H., et al. (2012). Novel therapeutics for the management of castration-resistant prostate cancer (CRPC). BJU International, 109(7), 968–985.PubMedCrossRefGoogle Scholar
  2. 2.
    de Bono, J. S., Oudard, S., Ozguroglu, M., Hansen, S., Machiels, J.-P., Kocak, I., et al. (2010). Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial. Lancet, 376(9747), 1147–1154.PubMedCrossRefGoogle Scholar
  3. 3.
    de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., et al. (2011). Abiraterone and increased survival in metastatic prostate cancer. New England Journal of Medicine, 364(21), 1995–2005.PubMedCrossRefGoogle Scholar
  4. 4.
    Parker, C., Heinrich, D., O’Sullivan, J. M., Fossá, S. D., Chodacki, A., Demkow, T., et al. (2011). Overall survival benefit of radium-223 chloride (alpharadin) in the treatment of patients with symptomatic bone metastases in castration-resistant prostate cancer (CRPC): A phase III randomized trial (ALSYMPCA). [abstract 1LBA]. European Journal of Cancer, 47(suppl 2), 3.CrossRefGoogle Scholar
  5. 5.
    Mukherji, D., Pezaro, C. J., & De-Bono, J. S. (2012). MDV3100 for the treatment of prostate cancer. Expert Opinion on Investigational Drugs, 21(2), 227–233.PubMedCrossRefGoogle Scholar
  6. 6.
    Fizazi, K., De Bono, J. S., Flechon, A., Heidenreich, A., Voog, E., Davis, N. B., et al. (2012). Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer. European Journal of Cancer, 48(1), 85–93.PubMedCrossRefGoogle Scholar
  7. 7.
    Chu, F. M., Picus, J., Fracasso, P. M., Dreicer, R., Lang, Z., & Foster, B. (2011). A phase 1, multicenter, open-label study of the safety of two dose levels of a human monoclonal antibody to human αv integrins, intetumumab, in combination with docetaxel and prednisone in patients with castrate-resistant metastatic prostate cancer. Investigational New Drugs, 29(4), 674–679.PubMedCrossRefGoogle Scholar
  8. 8.
    Atkinson, T. M., Mendoza, T. R., Sit, L., Passik, S., Scher, H. I., Cleeland, C., et al. (2010). The Brief Pain Inventory and its “pain at its worst in the last 24 hours” item: Clinical trial endpoint considerations. Pain Medicine, 11(3), 337–346.PubMedCrossRefGoogle Scholar
  9. 9.
    Esper, P., Mo, F., Chodak, G., Sinner, M., Cella, D., & Pienta, K. J. (1997). Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. Urology, 50(6), 920–928.PubMedCrossRefGoogle Scholar
  10. 10.
    Jensen, M. P. (2003). The validity and reliability of pain measures in adults with cancer. Journal of Pain, 4(1), 2–21.PubMedCrossRefGoogle Scholar
  11. 11.
    Melzack, R. (1975). The McGill Pain Questionnaire: Major properties and scoring methods. Pain, 1(3), 277–299.PubMedCrossRefGoogle Scholar
  12. 12.
    Rosenfeld, B., Roth, A. J., Gandhi, S., & Penson, D. (2004). Differences in health-related quality of life of prostate cancer patients based on stage of cancer. Psycho-oncology, 13(11), 800–807.PubMedCrossRefGoogle Scholar
  13. 13.
    Melzack, R., & Katz, J. (2001). The McGill Pain Questionnaire: Appraisal and current status. In D. C. Turk & R. Melzack (Eds.), Handbook of pain assessment (2nd ed., pp. 35–52). New York: Guilford Press.Google Scholar
  14. 14.
    Cella, D., Nichol, M. B., Eton, D., Nelson, J. B., & Mulani, P. (2009). Estimating clinically meaningful changes for the Functional Assessment of Cancer Therapy–prostate: Results from a clinical trial of patients with metastatic hormone-refractory prostate cancer. Value in Health, 12(1), 124–129.PubMedCrossRefGoogle Scholar
  15. 15.
    Webster, K., Cella, D., & Yost, K. (2003). The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties, applications, and interpretation. Health and Quality of Life Outcomes, 1, 79.PubMedCrossRefGoogle Scholar
  16. 16.
    Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., et al. (2004). Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. New England Journal of Medicine, 351(15), 1502–1512.PubMedCrossRefGoogle Scholar
  17. 17.
    Halabi, S., Vogelzang, N. J., Kornblith, A. B., Ou, S.-S., Kantoff, P. W., Dawson, N. A., et al. (2008). Pain predicts overall survival in men with metastatic castration-refractory prostate cancer. Journal of Clinical Oncology, 26(15), 2544–2549.PubMedCrossRefGoogle Scholar
  18. 18.
    Jensen, M. P. (2008). Pain assessment in clinical trials. In H. M. Wittink & D. B. Carr (Eds.), Pain management: Evidence, outcomes, and quality of life: A sourcebook (pp. 57–88). Philadelphia: Elsevier.Google Scholar
  19. 19.
    Ferreira-Valente, M. A., Pais-Ribeiro, J. L., & Jensen, M. P. (2011). Validity of four pain intensity rating scales. Pain, 152(10), 2399–2404.PubMedCrossRefGoogle Scholar
  20. 20.
    Cleeland, C. S., O’Mara, A., Zagari, M., & Baas, C. (2011). Integrating pain metrics into oncology clinical trials. Clinical Cancer Research, 17(21), 6646–6650.PubMedCrossRefGoogle Scholar
  21. 21.
    Basch, E. M., Sit, L., Fruscione, M., Burke, L., Kane, R., George, D., et al. (2009). Pain and analgesic use in men with metastatic prostate cancer [abstract]. Journal of Clinical Oncology, 27(Suppl, 15S), e20515.Google Scholar
  22. 22.
    Sandblom, G., Carlsson, P., Sigsjö, P., & Varenhorst, E. (2001). Pain and health-related quality of life in a geographically defined population of men with prostate cancer. British Journal of Cancer, 85(4), 497–503.PubMedCrossRefGoogle Scholar
  23. 23.
    Sullivan, P. W., Mulani, P. M., Fishman, M., & Sleep, D. (2007). Quality of life findings from a multicenter, multinational, observational study of patients with metastatic hormone-refractory prostate cancer. Quality of Life Research, 16(4), 571–575.PubMedCrossRefGoogle Scholar
  24. 24.
    Berthold, D. R., Pond, G. R., Roessner, M., de Wit, R., Eisenberger, M., & Tannock, A. I. (2008). Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: Relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study. Clinical Cancer Research, 14(9), 2763–2767.PubMedCrossRefGoogle Scholar
  25. 25.
    Collette, L., van Andel, G., Bottomley, A., Oosterhof, G. O., Albrecht, W., de Reijke, T. M., et al. (2004). Is baseline quality of life useful for predicting survival with hormone-refractory prostate cancer? A pooled analysis of three studies of the European Organisation for Research and Treatment of Cancer Genitourinary Group. Journal of Clinical Oncology, 22(19), 3877–3885.PubMedCrossRefGoogle Scholar
  26. 26.
    Sullivan, P. W., Nelson, J. B., Mulani, P. M., & Sleep, D. (2006). Quality of life as a potential predictor for morbidity and mortality in patients with metastatic hormone-refractory prostate cancer. Quality of Life Research, 15(8), 1297–1306.PubMedCrossRefGoogle Scholar
  27. 27.
    Armstrong, A. J., Garrett-Mayer, E., Ou Yang, Y.-C., Carducci, M. A., Tannock, I., de Wit, R., et al. (2007). Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. Journal of Clinical Oncology, 25(25), 3965–3970.PubMedCrossRefGoogle Scholar
  28. 28.
    Scher, H. I., Halabi, S., Tannock, I., Morris, M., Sternberg, C. N., Carducci, M. A., et al. (2008). Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group. Journal of Clinical Oncology, 26(7), 1148–1159.PubMedCrossRefGoogle Scholar
  29. 29.
    Armstrong, A. J., Garrett-Mayer, E. S., Yang, Y.-C., de Wit, R., Tannock, I. F., & Eisenberger, M. (2007). A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: A TAX327 study analysis. Clinical Cancer Research, 13(21), 6396–6403.PubMedCrossRefGoogle Scholar
  30. 30.
    Fayers, P. M., Hopwood, P., Harvey, A., Girling, D. J., Machin, D., & Stephens, R. (1997). Quality of life assessment in clinical trials–guidelines and a checklist for protocol writers: The U.K. Medical Research Council experience. MRC Cancer Trials Office. European Journal of Cancer, 33(1), 20–28.PubMedCrossRefGoogle Scholar
  31. 31.
    Hahn, E. A., Webster, K. A., Cella, D., & Fairclough, D. L. (1998). Missing data in quality of life research in Eastern Cooperative Oncology Group (ECOG) clinical trials: Problems and solutions. Statistics in Medicine, 17(5–7), 547–559.PubMedCrossRefGoogle Scholar
  32. 32.
    Hopwood, P., Harvey, A., Davies, J., Stephens, R. J., Girling, D. J., Gibson, D., et al. (1998). Survey of the Administration of quality of life (QL) questionnaires in three multicentre randomised trials in cancer. The Medical Research Council Lung Cancer Working Party the CHART Steering Committee. European Journal of Cancer, 34(1), 49–57.PubMedCrossRefGoogle Scholar
  33. 33.
    Shrout, P. E., & Fleiss, J. L. (1979). Intraclass correlations: Uses in assessing rater reliability. Psychological Bulletin, 86(2), 420–428.PubMedCrossRefGoogle Scholar
  34. 34.
    Deyo, R. A., Diehr, P., & Patrick, D. L. (1991). Reproducibility and responsiveness of health status measures. Statistics and strategies for evaluation. Controlled Clinical Trials, 12(4 Suppl), 142S–158S.PubMedCrossRefGoogle Scholar
  35. 35.
    Hays, R. D., & Revicki, D. A. (2005). Reliability and validity, including responsiveness. In P. Fayers & R. Hays (Eds.), Assessing quality of life in clinical trials: Methods and practice (2nd ed., pp. 25–39). Oxford: Oxford University Press.Google Scholar
  36. 36.
    Yuen, K. K., Shelley, M., Sze, W. M., Wilt, T. J., & Mason, M. (2006). Bisphosphonates for advanced prostate cancer. Cochrane Database of Systematic Reviews (4), CD006250.Google Scholar
  37. 37.
    Wong, R. & Wiffen, P. J. (2002). Bisphosphonates for the relief of pain secondary to bone metastases. Cochrane Database Systematic Reviews (2), CD002068.Google Scholar
  38. 38.
    Mercadante, S., & Fulfaro, F. (2005). World Health Organization guidelines for cancer pain: A reappraisal. Annals of Oncology, 16(Suppl 4), iv132–iv135.PubMedGoogle Scholar
  39. 39.
    Bader, P., Echtle, D., Fonteyne, V., Livadas, K., De Meerleer, G., Paez Borda, A., et al. (2012). Prostate cancer pain management: EAU guidelines on pain management. World Journal of Urology, 30(5), 677–686.PubMedCrossRefGoogle Scholar
  40. 40.
    Turk, D. C., Dworkin, R. H., Allen, R. R., Bellamy, N., Brandenburg, N., Carr, D. B., et al. (2003). Core outcome domains for chronic pain clinical trials: IMMPACT recommendations. Pain, 106(3), 337–345.PubMedCrossRefGoogle Scholar
  41. 41.
    Dworkin, R. H., Turk, D. C., Wyrwich, K. W., Beaton, D., Cleeland, C. S., Farrar, J. T., et al. (2008). Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. Journal of Pain, 9(2), 105–121.PubMedCrossRefGoogle Scholar
  42. 42.
    Schulz, K. F., & Grimes, D. A. (2005). Multiplicity in randomised trials I: Endpoints and treatments. Lancet, 365(9470), 1591–1595.PubMedCrossRefGoogle Scholar
  43. 43.
    Turk, D. C., Dworkin, R. H., McDermott, M. P., Bellamy, N., Burke, L. B., Chandler, J. M., et al. (2008). Analyzing multiple endpoints in clinical trials of pain treatments: IMMPACT recommendations. Initiative on methods, measurement, and pain assessment in clinical trials. Pain, 139(3), 485–493.PubMedCrossRefGoogle Scholar
  44. 44.
    Ahles, T. A., Herndon, J. E, 2nd, Small, E. J., Vogelzang, N. J., Kornblith, A. B., Ratain, M. J., et al. (2004). Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma: Results of Intergroup O159/Cancer and Leukemia Group B 9480. Cancer, 101(10), 2202–2208.PubMedCrossRefGoogle Scholar
  45. 45.
    Berry, D. L., Moinpour, C. M., Jiang, C. S., Ankerst, D. P., Petrylak, D. P., Vinson, L. V., et al. (2006). Quality of life and pain in advanced stage prostate cancer: Results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone. Journal of Clinical Oncology, 24(18), 2828–2835.PubMedCrossRefGoogle Scholar
  46. 46.
    Oh, W. K., Manola, J., Babcic, V., Harnam, N., & Kantoff, P. W. (2006). Response to second-line chemotherapy in patients with hormone refractory prostate cancer receiving two sequences of mitoxantrone and taxanes. Urology, 67(6), 1235–1240.PubMedCrossRefGoogle Scholar
  47. 47.
    Wu, E. Q., Mulani, P., Farrell, M. H., & Sleep, D. (2007). Mapping FACT-P and EORTC QLQ-C30 to patient health status measured by EQ-5D in metastatic hormone-refractory prostate cancer patients. Value in Health, 10(5), 408–414.PubMedCrossRefGoogle Scholar
  48. 48.
    Weinfurt, K. P., Li, Y., Castel, L. D., Saad, F., Timbie, J. W., Glendenning, G. A., et al. (2005). The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Annals of Oncology, 16(4), 579–584.PubMedCrossRefGoogle Scholar
  49. 49.
    Gater, A., Abetz-Webb, L., Battersby, C., Parasuraman, B., McIntosh, S., Nathan, F., et al. (2011). Pain in castration-resistant prostate cancer with bone metastases: A qualitative study. Health and Quality of Life Outcomes, 9(88).Google Scholar
  50. 50.
    Farrar, J. T. (2010). Advances in clinical research methodology for pain clinical trials. Nature Medicine, 16(11), 1284–1293.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2013

Authors and Affiliations

  • Donald W. RobinsonJr.
    • 1
  • Ning Zhao
    • 1
  • Fitzroy Dawkins
    • 2
  • Ming Qi
    • 2
  • Dennis Revicki
    • 3
  1. 1.Janssen Global Services, LLCMalvernUSA
  2. 2.Janssen Research & Development, LLCSpring HouseUSA
  3. 3.United BioSource CorporationBethesdaUSA

Personalised recommendations